Global PBC Therapeutics Market Expected to Reach $1.4 Billion by 2032, Driven by Rising Incidence of PBC - ResearchAndMarkets.com
The global Primary Biliary Cholangitis (PBC) Therapeutics market, valued at $683.95 million in 2022, is projected to grow significantly, reaching an estimated $1.4 billion by 2032, with a CAGR of 7.1% from 2023 to 2032.
- The global Primary Biliary Cholangitis (PBC) Therapeutics market, valued at $683.95 million in 2022, is projected to grow significantly, reaching an estimated $1.4 billion by 2032, with a CAGR of 7.1% from 2023 to 2032.
- PBC Therapeutics refer to treatment options for managing and treating primary biliary cholangitis, a chronic autoimmune liver disease that primarily affects the small bile ducts within the liver.
- Rising PBC Cases: The market's growth is driven by a surge in cases of primary biliary cholangitis and increasing awareness of the disease.
- Advancements in Therapeutics: The continuous development and research of PBC therapeutics worldwide are propelling market growth.